[1]NICHOLSON J K,LINDON J C, HOLMES E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data [J]. Xenobiotica, 1999, 29(11): 1181-9.[2]GU F L, XIA T L, KONG X T. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China [J]. Urology, 1994, 44(5): 688-91.[3]任毅, 王瑶, 郑入文. 良性前列腺增生病因及发病机制的研究现状 [J]. 世界中医药, 2018, 13(09): 2372-6.[4]CUNHA G R,VEZINA C M,ISAACSON D,et al. Development of the human prostate [J]. Differentiation, 2018, 103: 24-45.[5]MARTIN S A, HAREN M T, MARSHALL V R, et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men [J]. World J Urol, 2011, 29(2): 179-84.[6]ABRAMS P,CARDOZO L,FALL M,et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society [J]. Urology, 2003, 61(1): 37-49.[7]HE Q, WANG Z, LIU G, et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links [J]. Prostate Cancer Prostatic Dis, 2016, 19(1): 7-13.[8]BANERJEE P P, BANERJEE S, BROWN T R, et al. Androgen action in prostate function and disease [J]. Am J Clin Exp Urol, 2018, 6(2): 62-77.[9]DJAVAN B, REMZI M, ERNE B, et al. The pathophysiology of benign prostatic hyperplasia [J]. Drugs Today (Barc), 2002, 38(12): 867-76.[10]CSIKóS E, HORVáTH A, ÁCS K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs [J]. Molecules, 2021, 26(23).[11]郭琳, 苗明三. 基于前列腺增生症临床病症特点的动物模型分析 [J]. 中华中医药杂志, 2016, 31(01): 261-4.[12]WANG K, FAN D D, JIN S, et al. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications [J]. Asian J Androl, 2014, 16(2): 274-9.[13]PRINS G S, KORACH K S. The role of estrogens and estrogen receptors in normal prostate growth and disease [J]. Steroids, 2008, 73(3): 233-44.[14]NICHOLSON T M, RICKE W A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future [J]. Differentiation, 2011, 82(4-5): 184-99.[15]HABENICHT U F, EL ETREBY M F. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies [J]. J Androl, 1991, 12(6): 395-402.[16]OMRAN A, LECA B M, OŠTARIJAŠ E, et al. Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors [J]. Ther Adv Endocrinol Metab, 2021, 12: 20420188211066210.[17]LEE S Y, KIM M, JUNG S, et al. Altered plasma lysophosphatidylcholines and amides in non-obese and non-diabetic subjects with borderline-to-moderate hypertriglyceridemia: a case-control study [J]. PLoS One, 2015, 10(4): e0123306.[18]RUSSO G I, LARGANà G, SEBASTIANELLI A, et al. The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review [J]. J Clin Med, 2021, 10(3).[19]NIAN L, SHUKANG G, SHASHA W, et al. Aerobic exercises ameliorate benign prostatic hyperplasia via IGF-1/IGF-1R/ERK/AKT signalling pathway in prostate tissue of high-fat-diet-fed mice with insulin resistance [J]. Steroids, 2021, 175: 108910.[20]OZDEN C, OZDAL O L, URGANCIOGLU G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia [J]. Eur Urol, 2007, 51(1): 199-203; discussion 4-6.[21]PLOUMIDOU K, KYROUDI-VOULGARI A, PEREA D, et al. Effect of a hypercholesterolemic diet on serum lipid profile, plasma sex steroid levels, and prostate structure in rats [J]. Urology, 2010, 76(6): 1517.e1-5.[22]HWANG E C, KIM S O, NAM D H, et al. Men with Hypertension are More Likely to Have Severe Lower Urinary Tract Symptoms and Large Prostate Volume [J]. Low Urin Tract Symptoms, 2015, 7(1): 32-6.[23]ZUSMAN R. Patients with uncontrolled hypertension orconcomitant hypertension and benign prostatic hyperplasia [J]. Clin Cardiol, 2004, 27(2): 63-9.[24]NGAI H Y, YUEN K S, NG C M, et al. Metabolic syndrome and benign prostatic hyperplasia: An update [J]. Asian J Urol, 2017, 4(3): 164-73.[25]AZAMI G, SOH K L, SAZLINA S G, et al. Effect of a Nurse-Led Diabetes Self-Management Education Program on Glycosylated Hemoglobin among Adults with Type 2 Diabetes [J]. J Diabetes Res, 2018, 2018: 4930157.[26]PARSONS J K, CARTER H B, PARTIN A W, et al. Metabolic factors associated with benign prostatic hyperplasia [J]. J Clin Endocrinol Metab, 2006, 91(7): 2562-8.[27]VIKRAM A, JENA G, RAMARAO P. Insulin-resistance and benign prostatic hyperplasia: the connection [J]. Eur J Pharmacol, 2010, 641(2-3): 75-81.[28]ZHOU B, WANG P, XU W J, et al. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia [J]. Eur Rev Med Pharmacol Sci, 2018, 22(16): 5077-81.[29]WANG Y B, YANG L, DENG Y Q, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study [J]. J Transl Med, 2022, 20(1): 495.[30]KRISTAL A R, ARNOLD K B, SCHENK J M, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial [J]. J Urol, 2007, 177(4): 1395-400; quiz 591.[31]龙智, 何乐业, 钟狂飚, et al. 合并前列腺炎的良性前列腺增生症的临床分析 [J]. 中南大学学报(医学版), 2010, 35(04): 381-5.[32]LLOYD G L, MARKS J M, RICKE W A. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation? [J]. Curr Urol Rep, 2019, 20(9): 54.[33]CAO D,SUN R,PENG L,et al. Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging [J]. Frontiers in immunology, 2022, 13: 842008.[34]MACOSKA J A. Chemokines and BPH/LUTS [J]. Differentiation, 2011, 82(4-5): 253-60.[35]STEWART J, MCCALLIN T, MARTINEZ J, et al. Hyperlipidemia [J]. Pediatr Rev, 2020, 41(8): 393-402.[36]中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南 [J]. 中华心血管病杂志, 2007, 35(05): 390-419.[37]LI Q, GU W, MA X, et al. Amino Acid and Biogenic Amine Profile Deviations in an Oral Glucose Tolerance Test: A Comparison between Healthy and Hyperlipidaemia Individuals Based on Targeted Metabolomics [J]. Nutrients, 2016, 8(6).[38]曲冬颖, 贾连群, 甄毕贤, et al. 妊娠高脂血症患者血浆代谢组学研究 [J]. 中国实用妇科与产科杂志, 2017, 33(04): 401-7.[39]WANG Y, LIU D, LI Y, et al. Metabolomic analysis of serum from obese adults with hyperlipemia by UHPLC-Q-TOF MS/MS [J]. Biomed Chromatogr, 2016, 30(1): 48-54.[40]ALSEEKH S, AHARONI A, BROTMAN Y, et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices [J]. Nat Methods, 2021, 18(7): 747-56.[41]AZAD R K, SHULAEV V. Metabolomics technology and bioinformatics for precision medicine [J]. Brief Bioinform, 2019, 20(6): 1957-71.[42]WANG T J, LARSON M G, VASAN R S, et al. Metabolite profiles and the risk of developing diabetes [J]. Nat Med, 2011, 17(4): 448-53.[43]ROBINSON J I, WEIR W H, CROWLEY J R, et al. Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections [J]. J Clin Invest, 2019, 129(9): 3792-806.[44]LOURENçO C,KELLY D, CANTILLON J, et al. Monitoring type 2 diabetes from volatile faecal metabolome in Cushing's syndrome and single Afmid mouse models via a longitudinal study [J]. Sci Rep, 2019, 9(1): 18779.[45]XU E Y, SCHAEFER W H, XU Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways [J]. Curr Opin Drug Discov Devel, 2009, 12(1): 40-52.[46]ARNETH B, ARNETH R, SHAMS M. Metabolomics of Type 1 and Type 2 Diabetes [J]. Int J Mol Sci, 2019, 20(10).
